Director Declaration
18 August 2016 13:00
New external board appointment
Listing Rule LR 9.6.14 R (2)
Graham Chipchase, a Non-Executive Director of AstraZeneca PLC, has been appointed as Chief Executive Officer and a Director of Brambles Limited, a company listed on the Australian Securities Exchange, effective from 2017.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries | ||
Neil Burrows | UK/Global | +44 203 749 5637 |
Vanessa Rhodes | UK/Global | +44 203 749 5736 |
Karen Birmingham | UK/Global | +44 203 749 5634 |
Rob Skelding | UK/Global | +44 203 749 5821 |
Jacob Lund | Sweden | +46 8 553 260 20 |
Michele Meixell | US | +1 302 885 2677 |
Investor Relations | ||
UK | ||
Thomas Kudsk Larsen | +44 203 749 5712 | |
Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 |
Nick Stone | Respiratory & Autoimmunity | +44 203 749 5716 |
Henry Wheeler | Oncology | +44 203 749 5797 |
Christer Gruvris | Infection & Neuroscience | +44 203 749 5711 |
US | ||
Lindsey Trickett | Cardiovascular & Metabolic Diseases | +1 240 543 7970 |
Mitchell Chan | Oncology | +1 240 477 3771 |
Toll-free | +1 866 381 7277 |
Adrian Kemp
Company Secretary
AstraZeneca PLC
-ENDS-